IES20180266A2 - 2-furanacrylic acid drug intermediates synthesis method - Google Patents
2-furanacrylic acid drug intermediates synthesis methodInfo
- Publication number
- IES20180266A2 IES20180266A2 IES20180266A IES20180266A2 IE S20180266 A2 IES20180266 A2 IE S20180266A2 IE S20180266 A IES20180266 A IE S20180266A IE S20180266 A2 IES20180266 A2 IE S20180266A2
- Authority
- IE
- Ireland
- Prior art keywords
- solution
- added
- synthesis method
- acid drug
- drug intermediates
- Prior art date
Links
- ZCJLOOJRNPHKAV-ONEGZZNKSA-N (e)-3-(furan-2-yl)prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=CO1 ZCJLOOJRNPHKAV-ONEGZZNKSA-N 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 2
- 239000000543 intermediate Substances 0.000 title abstract 2
- 238000001308 synthesis method Methods 0.000 title abstract 2
- 239000000243 solution Substances 0.000 abstract 5
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 abstract 3
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 abstract 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 abstract 2
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- XITGHTRVSNMXOD-UHFFFAOYSA-N [Nb].ClOCl Chemical compound [Nb].ClOCl XITGHTRVSNMXOD-UHFFFAOYSA-N 0.000 abstract 1
- SMZOGRDCAXLAAR-UHFFFAOYSA-N aluminium isopropoxide Chemical compound [Al+3].CC(C)[O-].CC(C)[O-].CC(C)[O-] SMZOGRDCAXLAAR-UHFFFAOYSA-N 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 230000018044 dehydration Effects 0.000 abstract 1
- 238000006297 dehydration reaction Methods 0.000 abstract 1
- 235000006408 oxalic acid Nutrition 0.000 abstract 1
- 235000011164 potassium chloride Nutrition 0.000 abstract 1
- 239000001103 potassium chloride Substances 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 235000010344 sodium nitrate Nutrition 0.000 abstract 1
- 239000004317 sodium nitrate Substances 0.000 abstract 1
- 238000003756 stirring Methods 0.000 abstract 1
- KJIOQYGWTQBHNH-UHFFFAOYSA-N undecanol Chemical compound CCCCCCCCCCCO KJIOQYGWTQBHNH-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Furan Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The present invention discloses 2-furanacrylic acid drug intermediates synthesis method, comprises the following steps: furanacryl alcohol and sodium nitrate solution are added to the reaction vessel, the temperature is raised, aqueous solution is added, aluminum isopropoxide is added, continues to react; the niobium oxychloride powder is add in batches, then adds the potassium chloride solution, controls the stirring speed, continues to react, lowers the temperature, the oxalic acid solution is added to adjust the pH, washed with undecanol solution, recrystallizes in the cyclobutane solution, dehydrated with dehydration, gets the finished product 2-furanacrylic acid. <Figure 1>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710836678.7A CN108264497A (en) | 2017-09-17 | 2017-09-17 | The synthetic method of 2- furylacrylic acid pharmaceutical intermediates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IES20180266A2 true IES20180266A2 (en) | 2019-11-13 |
Family
ID=60159374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IES20180266 IES20180266A2 (en) | 2017-09-17 | 2018-08-23 | 2-furanacrylic acid drug intermediates synthesis method |
Country Status (4)
| Country | Link |
|---|---|
| CN (1) | CN108264497A (en) |
| AU (1) | AU2018101130A4 (en) |
| GB (1) | GB201715085D0 (en) |
| IE (1) | IES20180266A2 (en) |
-
2017
- 2017-09-17 CN CN201710836678.7A patent/CN108264497A/en active Pending
- 2017-09-19 GB GBGB1715085.5A patent/GB201715085D0/en not_active Ceased
-
2018
- 2018-08-11 AU AU2018101130A patent/AU2018101130A4/en not_active Ceased
- 2018-08-23 IE IES20180266 patent/IES20180266A2/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN108264497A (en) | 2018-07-10 |
| AU2018101130A4 (en) | 2018-09-06 |
| GB201715085D0 (en) | 2017-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IES20180266A2 (en) | 2-furanacrylic acid drug intermediates synthesis method | |
| IE20180280U1 (en) | Methylchloroperoxybenzoic acid drug intermediates synthesis method | |
| IE20180288U1 (en) | P-methoxphenylacetic acid drug intermediates synthesis method | |
| IE20180281U1 (en) | Benzoyl peroxide organic intermediates synthesis method | |
| IES20180263A2 (en) | Drug intermediates 3-methoxy-2-thiophenecarboxaldehyde synthesis method | |
| IES20180293A2 (en) | 1,2-naphthoquinone drug intermediates synthesis method | |
| IE20180284U1 (en) | 2,3-dihydroxy-succinic acid drug intermediates synthesis method | |
| IES20180291A2 (en) | Acetone dicarboxylic acid drug intermediates synthesis method | |
| IES20180267U1 (en) | Aminoquinone drug intermediates tetrachlorobenzoquinone synthesis method | |
| IES20180259A2 (en) | Drug intermediates n-methylpyridin-2-one synthesis method | |
| IES20180250A2 (en) | Butyraldehyde oxime drug itermediates synthesis method | |
| IES20180262A2 (en) | Drug intermediates 3,5-dimethoxybenzaldehyde synthesis method | |
| IES20180251U1 (en) | Nicotinamide-n-oxide drug intermediates synthesis method | |
| IE20180283U1 (en) | O-toluene formamide organic intermediates synthesis method | |
| IES20180275U1 (en) | Drug intermediates 3-oxoheptanone ethylene glycol synthesis method | |
| IES20180261A2 (en) | Drug intermediates 3,4,5-trimethoxybenzaldehyde synthesis method | |
| IES20180260U1 (en) | Drug intermediates 1-methyl-2-quinolinone synthesis method | |
| IES20180195A2 (en) | Pharmaceutical hormone intermediates 11-ketone-16α, 17α-epoxy progesterone synthesis method | |
| IE20180292U1 (en) | 7-(3,5,6-trimethyl-1,4-benzoquinon-2-yl)-7-phenyl heptanoic acid synthesis method | |
| IE20180290U1 (en) | P-aminobenzaldehyde drug intermediates synthesis method | |
| IE20180289U1 (en) | 2-nitro-4-aminobenzaldehyde drug intermediates synthesis method | |
| IE20180282U1 (en) | Dodecanoyl peroxide organic intermediates synthesis method | |
| IES20180107A2 (en) | Drug intermediates parachlorobenzoic-acid synthesis method | |
| IES20180203A2 (en) | Chlormadinone drug intermediates o-tetrachlorobenzoquinone synthesis method | |
| IES20180242U1 (en) | Broad spectrum antimicrobial agents thiamphenicol synthesis method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FJ9A | Application deemed to be withdrawn section 31(3) |